SCHEMBL30738031

SCHEMBL30738031

CCN(CC)CCCCNc1cc2nc(N)c(-c3cc(OC)cc(OC)c3)cc2cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 20/20 1.00
▸ KDR P35968 18/20 1.00
▸ FGFR2 P21802 12/20 1.00
▸ FGFR4 P22455 12/20 1.00
▸ FGFR3 P22607 12/20 1.00
▸ FLT1 P17948 10/20 0.68
▸ FLT4 P35916 10/20 0.68
▸ GLA P06280 1/20 0.49
▸ SRC P12931 1/20 0.49
▸ CSK P41240 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218125 1.00 FGFR1 (1.00) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL6056003 0.82 FGFR1 (0.70) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL16868903 0.80 FGFR1 (1.00) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL26928630 0.79 FGFR1 (1.00) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL6640513 0.78 FGFR1 (0.66) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL6639949 0.77 FGFR1 (0.63) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL6916832 0.77 FGFR1 (0.63) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL20943051 0.70 FGFR1 (0.75) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL31647879 0.69 FGFR1 (0.52) FGFR1KDRFGFR2FGFR4FGFR3
SCHEMBL8147144 0.68 FGFR1 (0.56) FGFR1KDRFGFR2FGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 — — WO claimed
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 — — WO disclosed
Send feedback